BVS Bioventus
- 6.380
- -0.250-3.77%
- 6.540
- +0.160+2.51%
Bioventus News
Bioventus: Poised for Growth Amidst Strategic Refinement and Debt Reduction
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Shares of AppLovin Corporation (NASDAQ:APP) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results.The company posted revenue of $1.
Apyx Medical Corporation Announces Board Leadership Transition
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.Shares of Exact Sciences Corporation (NASDAQ:EXAS) fell sharply in today's pre-market trading aft
Bioventus Is Maintained at Buy by Canaccord Genuity
Bioventus Is Maintained at Buy by Canaccord Genuity
Bioventus Price Target Raised to $8.00/Share From $7.00 by Canaccord Genuity
Bioventus Price Target Raised to $8.00/Share From $7.00 by Canaccord Genuity
Canadian Investment Banking Group: Maintaining the Bioventus (BVS.US) rating, adjusted from buy to buy rating, and adjusted the target price from $7.00 to $8.00.
Canadian Investment Banking Group: Maintaining the Bioventus (BVS.US) rating, adjusted from buy to buy rating, and adjusted the target price from $7.00 to $8.00.
Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $8
Canaccord Genuity analyst William Plovanic maintains Bioventus with a Buy and raises the price target from $7 to $8.
Bioventus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 61.27% Canaccord Genuity $7 → $8 Maintains Buy 03/13/2024 81.43% Craig-Hallum $6 → $9 Maintains
Bioventus Inc. (NASDAQ:BVS) Q1 2024 Earnings Call Transcript
Bioventus Inc (BVS) Q1 2024 Earnings Call Transcript Highlights: Strong Start With Significant ...
Q1 2024 Bioventus Inc Earnings Call
Nasdaq Moves Lower; Great Lakes Dredge & Dock Shares Surge Following Upbeat Earnings
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 0.2% on Tuesday.The Dow traded up 0.01% to 38,857.00 while the NASDAQ fell 0.20% to 16,316.79. The S&P 500
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Beyond, Inc. (NYSE:BYON) fell sharply during Tuesday's session following weaker-than-expected quarterly results.Beyond posted adjusted loss of $1.22 per share, versus estimates for a loss of
Bioventus BVS Guidance; Helius HSDT Offering
PEGY, MTC and IMTE Among Mid-day Movers
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersNuwellis (NASDAQ:NUWE) shares rose 57.7% to $0.27 during Tuesday's regular session. The company's market cap stands at $4.1 million. As per the news, the Q1 earnings report came out today. Biov
Bioventus, Inc. (BVS) Q1 2024 Earnings Call Transcript
Bioventus, Inc. (BVS) Q1 2024 Earnings Call Transcript
Bioventus Up Nearly 22%, On Track for Largest Percent Increase Since May 2023 -- Data Talk
Bioventus, Inc. Class A (BVS) is currently at $4.88, up $0.88 or 21.88% --Would be highest close since April 10, 2024, when it closed at $4.97 --On pace for largest percent increase since May 19, 20
NanoViricides, TC BioPharm, Holdco Nuvo Among Healthcare Movers
Analysis
Price Target
No Data
